NO971868L - Vaksine og antitoksin for behandling og forhindring av C.difficile-sykdom - Google Patents

Vaksine og antitoksin for behandling og forhindring av C.difficile-sykdom

Info

Publication number
NO971868L
NO971868L NO971868A NO971868A NO971868L NO 971868 L NO971868 L NO 971868L NO 971868 A NO971868 A NO 971868A NO 971868 A NO971868 A NO 971868A NO 971868 L NO971868 L NO 971868L
Authority
NO
Norway
Prior art keywords
difficile
antitoxin
antitoxins
treatment
humans
Prior art date
Application number
NO971868A
Other languages
English (en)
Other versions
NO971868D0 (no
NO323305B1 (no
Inventor
James A Williams
Nisha V Padhye
John A Kink
Bruce S Thalley
Douglas C Stafford
Joseph R Firca
Original Assignee
Ophidian Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/405,496 external-priority patent/US5919665A/en
Priority claimed from US08/480,604 external-priority patent/US5736139A/en
Application filed by Ophidian Pharm Inc filed Critical Ophidian Pharm Inc
Publication of NO971868D0 publication Critical patent/NO971868D0/no
Publication of NO971868L publication Critical patent/NO971868L/no
Publication of NO323305B1 publication Critical patent/NO323305B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19971868A 1994-10-24 1997-04-23 Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det. NO323305B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32915494A 1994-10-24 1994-10-24
US08/405,496 US5919665A (en) 1989-10-31 1995-03-16 Vaccine for clostridium botulinum neurotoxin
US42271195A 1995-04-14 1995-04-14
US08/480,604 US5736139A (en) 1989-10-31 1995-06-07 Treatment of Clostridium difficile induced disease
PCT/US1995/013737 WO1996012802A1 (en) 1989-10-31 1995-10-23 Vaccine and antitoxin for treatment and prevention of c. difficile disease

Publications (3)

Publication Number Publication Date
NO971868D0 NO971868D0 (no) 1997-04-23
NO971868L true NO971868L (no) 1997-06-24
NO323305B1 NO323305B1 (no) 2007-03-05

Family

ID=27502393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971868A NO323305B1 (no) 1994-10-24 1997-04-23 Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det.

Country Status (17)

Country Link
US (1) US6290960B1 (no)
EP (2) EP1041149B8 (no)
JP (2) JP2002514886A (no)
CN (1) CN1176658A (no)
AT (1) ATE366312T1 (no)
AU (1) AU709586B2 (no)
BR (1) BR9509903A (no)
CA (1) CA2203504A1 (no)
CZ (1) CZ296806B6 (no)
DE (1) DE69535530D1 (no)
FI (1) FI971732A (no)
HU (1) HUT78048A (no)
MX (1) MX9702955A (no)
NO (1) NO323305B1 (no)
NZ (2) NZ295998A (no)
PL (1) PL320214A1 (no)
WO (1) WO1996012802A1 (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
EP1105153A4 (en) * 1996-08-28 2005-01-19 Ophidian Pharm Inc POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM)
CA2265887A1 (en) * 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
AU7410798A (en) * 1996-11-29 1998-06-22 General Hospital Corporation, The Heterologous antigens in live cell V
US7179611B2 (en) * 1997-02-10 2007-02-20 Bd Lee Laboratories Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A
WO1998059053A1 (en) * 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1024826B1 (en) 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6780617B2 (en) 2000-12-29 2004-08-24 Chen & Chen, Llc Sample processing device and method
AU772778B2 (en) * 1998-07-13 2004-05-06 University Of Southern California Novel inhibitors of angiogenesis and tumor growth
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
AU781175B2 (en) * 1999-04-09 2005-05-12 Intercell Usa, Inc. Recombinant toxin A/toxin B vaccine against Clostridium Difficile
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1057895A1 (de) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
FR2796385A1 (fr) * 1999-07-16 2001-01-19 Inst Nat Sante Rech Med Methode de production d'anticorps dans le jaune d'oeuf et utilisation des anticorps ainsi obtenus
GB9921592D0 (en) 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
EP1427531B1 (en) 2001-09-11 2016-10-19 Iquum, Inc. Sample vessels
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1603674B1 (en) 2003-02-05 2016-01-06 Iquum, Inc. Sample processing
US9701737B2 (en) * 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
RS51908B (en) 2004-02-06 2012-02-29 University Of Massachusetts CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES
CA2575994A1 (en) * 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
DK1824991T3 (en) 2004-11-24 2016-03-29 Techlab Inc Device and method for the detection of analytes
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
CN100564527C (zh) * 2006-10-23 2009-12-02 中国人民解放军军事医学科学院生物工程研究所 A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
JP2008169142A (ja) * 2007-01-11 2008-07-24 Osaka Prefecture Univ 食中毒菌に対する抗体の産生方法
US9802988B2 (en) 2009-05-20 2017-10-31 University Of Maryland, Baltimore Engineered type IV pilin of Clostridium difficile
WO2010135585A2 (en) * 2009-05-20 2010-11-25 University Of Maryland, Baltimore Engineered type iv pilin of clostridium difficile
CA2782406A1 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP2753352B2 (en) * 2010-09-03 2022-08-10 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
CN102181457B (zh) * 2011-03-21 2012-07-04 王世霞 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
SI2714911T1 (sl) 2011-05-27 2017-03-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
WO2013082298A2 (en) * 2011-11-30 2013-06-06 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
FI3513806T3 (fi) 2012-12-05 2023-04-26 Glaxosmithkline Biologicals Sa Immunogeeninen koostumus
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
EP2969012A4 (en) 2013-03-12 2016-09-14 Univ Yale COMPOSITIONS AND METHODS FOR IDENTIFYING MICROBES RELATED TO SECRETORY ANTIBODIES
EP3160500B1 (en) 2014-06-25 2019-08-21 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
EP3453396A1 (en) * 2014-08-28 2019-03-13 Yale University Compositions and methods for treating an inflammatory disease or disorder
KR20240031420A (ko) 2015-06-12 2024-03-07 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
JP6612807B2 (ja) * 2017-03-29 2019-11-27 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
JP6964623B2 (ja) * 2017-03-29 2021-11-10 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
CN108822211B (zh) * 2018-06-05 2019-12-24 中国人民解放军军事科学院军事医学研究院 一种制备a、b、e、f型四价肉毒抗毒素的方法
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
ES2052496T3 (es) 1985-11-25 1994-07-16 Ghen Corp Sustancia que contiene anticuerpo especifico obtenida de huevos y metodo para su produccion y uso.
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5268295A (en) * 1991-05-31 1993-12-07 W. Alton Jones Cell Science Center, Inc. Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2120954A1 (en) * 1992-09-01 1994-01-20 Irwin J. Griffith Allergenic proteins and peptides from japanese cedar pollen
EP0593176A3 (en) * 1992-09-28 1995-03-01 Wisconsin Alumni Res Found Pharmaceutical compositions containing botulinum toxin and method of manufacture.
JPH06192296A (ja) * 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
US5480972A (en) * 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen

Also Published As

Publication number Publication date
NO971868D0 (no) 1997-04-23
WO1996012802A9 (en) 1999-09-16
CZ296806B6 (cs) 2006-06-14
EP1041149B1 (en) 2007-07-04
NZ337543A (en) 2002-06-28
US6290960B1 (en) 2001-09-18
EP0796326A4 (en) 2000-01-19
JP2003137897A (ja) 2003-05-14
BR9509903A (pt) 1997-11-25
CZ125097A3 (cs) 1998-03-18
FI971732A0 (fi) 1997-04-23
MX9702955A (es) 1998-07-31
DE69535530D1 (de) 2007-08-16
CA2203504A1 (en) 1996-05-02
AU3968395A (en) 1996-05-15
NO323305B1 (no) 2007-03-05
EP1041149A2 (en) 2000-10-04
FI971732A (fi) 1997-06-23
JP2002514886A (ja) 2002-05-21
PL320214A1 (en) 1997-09-15
CN1176658A (zh) 1998-03-18
NZ295998A (en) 1999-10-28
EP1041149A3 (en) 2001-05-02
EP1041149B8 (en) 2007-10-03
ATE366312T1 (de) 2007-07-15
AU709586B2 (en) 1999-09-02
HUT78048A (hu) 1999-07-28
JP3914484B2 (ja) 2007-05-16
WO1996012802A1 (en) 1996-05-02
EP0796326A1 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
NO971868L (no) Vaksine og antitoksin for behandling og forhindring av C.difficile-sykdom
DK534188D0 (da) Hidtil ukendt vaccine
DK1372708T3 (da) Vaccine til transkutan immunisering mod rejsediarre
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
RU93058676A (ru) Оральное лечение геликобактерной инфекции
AU7814498A (en) Multivalent (in ovo) avian vaccine
DE60032250D1 (de) Behandlung von Allergien
CA2022420A1 (en) Escherichia coli vaccine
BR9910749A (pt) Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
CY1107188T1 (el) Εμβολιο ε. coli πτηνου για την προστασια εναντι κολοβακτηριωσης
MXPA02004627A (es) Vacunas contra el micoplasma bovis y sus metodos de uso.
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
PT600396E (pt) Vacinas contra protozoarios intestinais
ATE435028T1 (de) Impfstoff gegen neisseria infektion
NO307815B1 (no) Levende eller inaktivert parental vaksine mot rotavirusinfeksjon
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
DK0535740T3 (da) Vaccine mod luftvejsinfektioner hos katte
DK0545951T3 (da) HRSV-vaccine
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
HUP0003164A2 (hu) A Helicobacter pylori FlgE polipeptidet tartalmazó vakcinakészítmények
EA202100185A2 (ru) Вакцина и способ повышения иммуногенности и специфической активности средств профилактики инфекций
Polotskiĭ et al. Protection from virulent Salmonella groups B and D after the peroral immunization of chicks with a hybrid of Salmonella typhimurium and Salmonella dublin
Mirchamsy et al. Oral Immunization against Diphtheria and Tetanus Infections by Fluid Dphtheria and Tetanus Toxoids